193 related articles for article (PubMed ID: 24264380)
1. Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation.
Beiras-Fernandez A; Weis F; Rothkopf J; Kaczmarek I; Ledderose C; Dick A; Keller T; Beiras A; Kreth S
Ann Transplant; 2013 Nov; 18():643-50. PubMed ID: 24264380
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of galectin-3 in patients with heart failure.
Bošnjak I; Selthofer-Relatić K; Včev A
Dis Markers; 2015; 2015():690205. PubMed ID: 25960597
[TBL] [Abstract][Full Text] [Related]
3. Galectin-3 in Patients with Acute Heart Failure: Preliminary Report on First Polish Experience.
Sygitowicz G; Tomaniak M; Filipiak KJ; Kołtowski Ł; Sitkiewicz D
Adv Clin Exp Med; 2016; 25(4):617-23. PubMed ID: 27629834
[TBL] [Abstract][Full Text] [Related]
4. Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation.
Coromilas E; Que-Xu EC; Moore D; Kato TS; Wu C; Ji R; Givens R; Jorde UP; Takayama H; Naka Y; George I; Mancini D; Schulze PC
BMC Cardiovasc Disord; 2016 Jun; 16():138. PubMed ID: 27301475
[TBL] [Abstract][Full Text] [Related]
5. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin.
López B; González A; Querejeta R; Zubillaga E; Larman M; Díez J
Eur J Heart Fail; 2015 Apr; 17(4):385-92. PubMed ID: 25684565
[TBL] [Abstract][Full Text] [Related]
6. Galectin-3 in heart failure with preserved ejection fraction.
de Boer RA; Edelmann F; Cohen-Solal A; Mamas MA; Maisel A; Pieske B
Eur J Heart Fail; 2013 Oct; 15(10):1095-101. PubMed ID: 23650131
[TBL] [Abstract][Full Text] [Related]
7. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients.
Lin YH; Lin LY; Wu YW; Chien KL; Lee CM; Hsu RB; Chao CL; Wang SS; Hsein YC; Liao LC; Ho YL; Chen MF
Clin Chim Acta; 2009 Nov; 409(1-2):96-9. PubMed ID: 19747906
[TBL] [Abstract][Full Text] [Related]
8. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.
Lopez-Andrès N; Rossignol P; Iraqi W; Fay R; Nuée J; Ghio S; Cleland JG; Zannad F; Lacolley P
Eur J Heart Fail; 2012 Jan; 14(1):74-81. PubMed ID: 22089058
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of plasma galectin-3 levels in patients with coronary heart disease and chronic heart failure.
Yu X; Sun Y; Zhao Y; Zhang W; Yang Z; Gao Y; Cai H; Li Y; Wang Q; Bian B; Nie J
Int Heart J; 2015 May; 56(3):314-8. PubMed ID: 25902879
[TBL] [Abstract][Full Text] [Related]
10. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure.
Gopal DM; Kommineni M; Ayalon N; Koelbl C; Ayalon R; Biolo A; Dember LM; Downing J; Siwik DA; Liang CS; Colucci WS
J Am Heart Assoc; 2012 Oct; 1(5):e000760. PubMed ID: 23316284
[TBL] [Abstract][Full Text] [Related]
11. Fibrosis marker syndecan-1 and outcome in patients with heart failure with reduced and preserved ejection fraction.
Tromp J; van der Pol A; Klip IT; de Boer RA; Jaarsma T; van Gilst WH; Voors AA; van Veldhuisen DJ; van der Meer P
Circ Heart Fail; 2014 May; 7(3):457-62. PubMed ID: 24647119
[TBL] [Abstract][Full Text] [Related]
12. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.
Anand IS; Rector TS; Kuskowski M; Adourian A; Muntendam P; Cohn JN
Eur J Heart Fail; 2013 May; 15(5):511-8. PubMed ID: 23291728
[TBL] [Abstract][Full Text] [Related]
13. Galectin-3: a novel mediator of heart failure development and progression.
de Boer RA; Voors AA; Muntendam P; van Gilst WH; van Veldhuisen DJ
Eur J Heart Fail; 2009 Sep; 11(9):811-7. PubMed ID: 19648160
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase C promotes cardiac fibrosis and heart failure by modulating galectin-3 expression.
Song X; Qian X; Shen M; Jiang R; Wagner MB; Ding G; Chen G; Shen B
Biochim Biophys Acta; 2015 Feb; 1853(2):513-21. PubMed ID: 25489662
[TBL] [Abstract][Full Text] [Related]
15. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction.
Sharma UC; Pokharel S; van Brakel TJ; van Berlo JH; Cleutjens JP; Schroen B; André S; Crijns HJ; Gabius HJ; Maessen J; Pinto YM
Circulation; 2004 Nov; 110(19):3121-8. PubMed ID: 15520318
[TBL] [Abstract][Full Text] [Related]
16. The biomarker plasma galectin-3 in advanced heart failure and survival with mechanical circulatory support devices.
Erkilet G; Özpeker C; Böthig D; Kramer F; Röfe D; Bohms B; Morshuis M; Gummert J; Milting H
J Heart Lung Transplant; 2013 Feb; 32(2):221-30. PubMed ID: 23352394
[TBL] [Abstract][Full Text] [Related]
17. Galectin-3 and fibulin-1 in systolic heart failure - relation to glucose metabolism and left ventricular contractile reserve.
Holmager P; Egstrup M; Gustafsson I; Schou M; Dahl JS; Rasmussen LM; Møller JE; Tuxen C; Faber J; Kistorp C
BMC Cardiovasc Disord; 2017 Jan; 17(1):22. PubMed ID: 28068900
[TBL] [Abstract][Full Text] [Related]
18. Practical experience using galectin-3 in heart failure.
McCullough PA
Clin Chem Lab Med; 2014 Oct; 52(10):1425-31. PubMed ID: 24810562
[TBL] [Abstract][Full Text] [Related]
19. [Galectin 3--a new biomarker for diagnostics and outcome of chronic heart failure].
Lakomkin SV; Skvortsov AA; Goriunova TV; Masenko VP; Tereshchenko SN
Kardiologiia; 2012; 52(3):45-52. PubMed ID: 22839443
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive review of the prognostic value of galectin-3 in heart failure.
Coburn E; Frishman W
Cardiol Rev; 2014; 22(4):171-5. PubMed ID: 24407048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
